Rebecca A Dent (Rebecca Dent)

Publication Activity (10 Years)

Years Active: 2021-2024
Publications (10 Years): 11

Top Topics

Locally Advanced

Sentinel Lymph Node

Neoadjuvant Chemotherapy

Placebo Controlled

Top Venues

Clinical cancer research : an official journal of the American Association for Cancer Research

Journal of the National Cancer Institute

Future oncology (London, England)

Science advances

This page only lists publications with an associated author ORCID identifier.

Publications

Tira Jing Ying Tan, Sarah L Sammons, Young-Hyuck Im, Lilin She, Kelly Mundy, Robert Bigelow, Tiffany A Traina, Carey K Anders, Joe Poh Sheng Yeong, Ezequiel Renzulli, Sung-Bae Kim, Rebecca A Dent
Phase II DORA Study of Olaparib with or without Durvalumab as a Chemotherapy-Free Maintenance Strategy in Platinum-Pretreated Advanced Triple-Negative Breast Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research 30 (7) (2024)
Rebecca A Dent, Javier Cortés, Lajos Pusztai, Heather McArthur, Sherko Kümmel, Jonas Bergh, Carsten Denkert, Yeon Hee Park, Rina Hui, Nadia Harbeck, Masato Takahashi, Michael Untch, Peter A Fasching, Fatima Cardoso, Amin Haiderali, Liyi Jia, Allison Martin Nguyen, Wilbur Pan, Joyce O'Shaughnessy, Peter Schmid
Neoadjuvant pembrolizumab+chemotherapy/adjuvant pembrolizumab for Early-Stage Triple-Negative breast cancer: Quality-of-Life results from randomized KEYNOTE-522 study. Journal of the National Cancer Institute (2024)
Rebecca A Dent, Javier Cortés, Lajos Pusztai, Heather McArthur, Sherko Kümmel, Jonas Bergh, Carsten Denkert, Yeon Hee Park, Rina Hui, Nadia Harbeck, Masato Takahashi, Michael Untch, Peter A Fasching, Fatima Cardoso, Amin Haiderali, Liyi Jia, Allison Martin Nguyen, Wilbur Pan, Joyce O'Shaughnessy, Peter Schmid
Neoadjuvant pembrolizumab+chemotherapy/adjuvant pembrolizumab for Early-Stage Triple-Negative breast cancer: Quality-of-Life results from randomized KEYNOTE-522 study. Journal of the National Cancer Institute (2024)
Tira Jing Ying Tan, Sarah L Sammons, Young-Hyuck Im, Lilin She, Kelly Mundy, Robert Bigelow, Tiffany A Traina, Carey K Anders, Joe Poh Sheng Yeong, Ezequiel Renzulli, Sung-Bae Kim, Rebecca A Dent
Phase II DORA Study of Olaparib with or without Durvalumab as a Chemotherapy-Free Maintenance Strategy in Platinum-Pretreated Advanced Triple-Negative Breast Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research (2024)
Rebecca A Dent, Sung-Bae Kim, Mafalda Oliveira, Carlos Henrique Barrios, Joyce O'Shaughnessy, Steven Jay Isakoff, Shigehira Saji, Rui Gilberto Ferreira, Manuel Philco, Igor Bondarenko, Qinshu Lian, Denise Bradley, Heather Hinton, Matthew J Wongchenko, Sarah-Jayne Reilly, Nicholas C Turner
Ipatasertib plus Paclitaxel for patients with PIK3CA/AKT1/PTEN-Altered Locally Advanced Unresectable or Metastatic Triple-Negative Breast Cancer in the IPATunity130 Phase III Trial. Clinical cancer research : an official journal of the American Association for Cancer Research (2024)
Tira Jing Ying Tan, Sarah L Sammons, Young-Hyuck Im, Lilin She, Kelly Mundy, Robert Bigelow, Tiffany A Traina, Carey K Anders, Joe Poh Sheng Yeong, Ezequiel Renzulli, Sung-Bae Kim, Rebecca A Dent
Phase II DORA Study of Olaparib with or without Durvalumab as a Chemotherapy-Free Maintenance Strategy in Platinum-Pretreated Advanced Triple-Negative Breast Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research 30 (7) (2024)
Rebecca A Dent, David W Cescon, Thomas Bachelot, Kyung Hae Jung, Zhi-Ming Shao, Shigehira Saji, Tiffany A Traina, Petra Vukovic, Darlington Mapiye, Micah J Maxwell, Peter Schmid, Javier Cortés
TROPION-Breast02: Datopotamab deruxtecan for locally recurrent inoperable or metastatic triple-negative breast cancer. Future oncology (London, England) (2023)
Peter Schmid, Nicholas C Turner, Carlos Henrique Barrios, Steven Jay Isakoff, Sung-Bae Kim, Marie-Paule Sablin, Shigehira Saji, Peter Savas, Gregory A Vidal, Mafalda Oliveira, Joyce O'Shaughnessy, Antoine Italiano, Enrique Espinosa, Valentina Boni, Shane White, Beatriz Rojas, Rui Gilberto Ferreira, Yee Soo Chae, Igor Bondarenko, Jieun Lee, Cesar Torres Mattos, Jorge Luis Martinez Rodriguez, Lisa H Lam, Surai Jones, Sarah-Jayne Reilly, Xiayu Huang, Kalpit Shah, Rebecca A Dent
First-Line Ipatasertib, Atezolizumab, and Taxane Triplet for Metastatic Triple-Negative Breast Cancer: Clinical and Biomarker Results. Clinical cancer research : an official journal of the American Association for Cancer Research (2023)
Joanne Wing Yan Chiu, Soo-Chin Lee, Chung Man James Ho, Yeon Hee Park, Ta-Chung Chao, Sung-Bae Kim, Elgene Lim, Ching-Hung Lin, Sherene Loi, Su Ying Low, Lynette Li San Teo, Winnie Yeo, Rebecca A Dent
Clinical Guidance on the Monitoring and Management of Trastuzumab Deruxtecan (T-DXd)-Related Adverse Events: Insights from an Asia-Pacific Multidisciplinary Panel. Drug safety (2023)
Rebecca A Dent, Mafalda Oliveira, Steven J Isakoff, Seock-Ah Im, Marc Espié, Sibel Blau, Antoinette R Tan, Cristina Saura, Matthew J Wongchenko, Na Xu, Denise Bradley, Sarah-Jayne Reilly, Aruna Mani, Sung-Bae Kim, null null
Final results of the double-blind placebo-controlled randomized phase 2 LOTUS trial of first-line ipatasertib plus paclitaxel for inoperable locally advanced/metastatic triple-negative breast cancer. Breast cancer research and treatment 189 (2) (2021)
Ser Yue Loo, Li Ping Toh, William Haowei Xie, Elina Pathak, Wilson Tan, Siming Ma, May Yin Lee, S Shatishwaran, Joanna Zhen Zhen Yeo, Ju Yuan, Yin Ying Ho, Esther Kai Lay Peh, Magendran Muniandy, Federico Torta, Jack Junjie Chan, Tira Jing Ying Tan, Yirong R Sim, Veronique Kiak Mien Tan, Kiat Tee Benita Tan, Preetha Madhukumar, Wei Sean Yong, Kong Wee Ong, Chow Yin Wong, Puay Hoon Tan, Yoon Sim Yap, Lih-Wen Deng, Rebecca A Dent, Roger Sik Yin Foo, Markus R Wenk, Soo-Chin Lee, Ying Swan Ho, Elaine Hsuen Lim, Wai Leong Tam
Fatty acid oxidation is a druggable gateway regulating cellular plasticity for driving metastasis in breast cancer. Science advances 7 (41) (2021)